ストックスクリーナーアプリを入手
257.58
1.06%
2.82
Abbvie Inc (ABBV) 最新ニュース
Global markets live: Broadcom, Meta, Walmart, Intel, AbbVie… - marketscreener.com
EC approves AbbVie’s Tepkinly combination for follicular lymphoma - Pharmaceutical Business review -
The Dividend ETF Quietly Outperforming the S&P 500 - The Motley Fool
AbbVie Inc. outlines long-term growth strategy as a major biopharma player - AD HOC NEWS
AbbVie (ABBV) Lowers Q2 Earnings Guidance Amid IPR&D Expenses - GuruFocus
AbbVie (ABBV) Adjusted EPS Guidance for Q2 Signals Slight Underp - GuruFocus
AbbVie revises guidance; expects Q2 EPS to include unfavorable impact of $0.17 - MSN
AbbVie Inc. stock underperforms Monday when compared to competitors - MarketWatch
AbbVie (ABBV) Receives EU Approval for TEPKINLY in Follicular Ly - GuruFocus
AbbVie Announces TEPKINLY® in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma - Investing News Network
Abbvie Says Tepkinly In Combination With Lenalidomide And Rituximab Approved By European Commission - TradingView
AbbVie's Post-Humira Triumph: Skyrizi and Rinvoq Drive Sector-Leading Growth - Kavout | AI
Will Immunology Franchise Aid AbbVie's Upcoming Q2 Results? - The Globe and Mail
HSBC Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $300 - Moomoo
ABBV Maintained by Cantor Fitzgerald -- Price Target Raised to $265 - GuruFocus
AbbVie Inc. (ABBV) Stock Analysis: Navigating a High Dividend Yield Amid Market Dynamics - DirectorsTalk Interviews
The Zacks Analyst Blog Highlights Applied Materials, Mastercard, AbbVie, INNOVATE and BranchOut - Zacks Investment Research
CBOE Vest S&P 500 Dividend Aristocrats Target Income ETF's AbbVie Inc(ABBV) Holding History - GuruFocus
Q1 Earnings Highlights: AbbVie (NYSE:ABBV) Vs The Rest Of The Therapeutics Stocks - Yahoo Finance
ABBVAbbvie Inc Latest SEC Filings - Finviz
AbbVie to buy Apogee Therapeutics (APGE) for $135.11 per share — significant premium - Stock Titan
AbbVie Inc (ABBV) Shares Surge 4.0% -- What GF Score of 82 Tells Investors - GuruFocus
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
Top Research Reports for Applied Materials, Mastercard & AbbVie - Zacks Investment Research
AbbVie Inc Stock (ABBV) Moved Up by 3.44% on Jul 2: Drivers Behind the Movement - TradingKey
AbbVie (ABBV) Reaches 52-Week High Amid Proposed Changes to Drug Pricing Program - GuruFocus
AbbVie, Other Healthcare Stocks Rise as Trump Administration Reportedly Targets Hospital Drug Markups - Moomoo
J&J or AbbVie: Which Stock Deserves a Place in Your Portfolio Now? - TradingView
AbbVie: Apogee Deal Just Widened An Already Dominant Moat - Seeking Alpha
AbbVie Inc. (ABBV) Hits New Milestone with Venetoclax on Chronic Lymphocytic Leukemia (CLL) Treatment - Yahoo Finance
Here's How Much $1000 Invested In AbbVie 5 Years Ago Would Be Worth Today - Benzinga
RBC Capital reiterates Abbvie stock Outperform rating at $260 By Investing.com - Investing.com Canada
Galderma Slumps After FDA Turns Down Botox Rival Relfydess - The Business of Fashion
AbbVie (ABBV) Shares Dip After Six-Day Surge Amid $10.9B Acquisi - GuruFocus
This Pharmaceutical Giant Just Poured $11 Billion on an Acquisition. Time to Buy? - The Motley Fool
AbbVie shares fell after six-session winning streak - MSN
AbbVie Inc. stock outperforms competitors despite losses on the day - MarketWatch
Bristol, Merck, AbbVie face House committee probe over China trials - Seeking Alpha
What Sparked the $43B Jump in AbbVie's Market Cap in the Past Week? - TradingView
Genmab/AbbVie Lymphoma Trial Meets Main Goal, Analyst Eyes Bigger Market Opportunity - Benzinga
Merck, AbbVie probed by US lawmakers over China clinical trials: report - Yahoo! Finance Canada
US lawmakers probe Merck and AbbVie China clinical trials - grafa.com
AbbVie, Genmab Blood-Cancer Drug Has Competitive Profile -- Market Talk - Moomoo
STIFEL FINANCIAL CORP's AbbVie Inc(ABBV) Holding History - GuruFocus
Why is AbbVie stock slipping today? By Investing.com - Investing.com Canada
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Merck, AbbVie investigated over China military hospital drug trials - Yahoo Finance
AbbVie, Merck Investigated by US House Committee Over Clinical Trials in China - marketscreener.com
Exclusive-US House committee opens investigation into Merck, AbbVie China drug trials - Yahoo! Finance Canada
US House committee opens investigation into Merck, AbbVie China drug trials - marketscreener.com
Nxera reaches fourth R&D milestone under AbbVie accord - The Pharma Letter
AbbVie Stock 6-Day Winning Spree: Stock Climbs 17% - Trefis
Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases - marketscreener.com
Nxera Pharma Co LtdNxera Pharma To Receive Us$10 Million Milestone Payment From Abbvie Under Collaboration Targeting Neurological Diseases - TradingView
AbbVie Climbs to 52-Week High: Is the Pharma Giant Still Worth Buying? - NAI500
AbbVie (ABBV) Reports Positive Results for Epkinly in Lymphoma T - GuruFocus
AbbVie (ABBV) Reports Positive Phase 3 Trial Results for DLBCL T - GuruFocus
Juvederm Users Say AbbVie Hid Risks Of Filler - Law360
Is AbbVie (ABBV) One of the 10 Best July Dividend Stocks to Buy? - Insider Monkey
AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma - marketscreener.com
AbbVie lymphoma trial cuts progression risk 60% in Phase 3 test - Stock Titan
AbbVie Stock Rockets 17% With 5-Day Winning Streak - Yahoo Finance
AbbVie (ABBV) Stock After 1-Year 41% Rally And Apogee Deal Valuation Check - Yahoo Finance Singapore
What's Going On With AbbVie Stock Monday?AbbVie (NYSE:ABBV) - Benzinga
AbbVie Stock Hits a New 52-Week High. Has It Gotten Too Expensive to Buy? - AOL.com
AbbVie (ABBV) Wins Backing For Two RINVOQ Skin Disease Uses In Europe - Yahoo Finance
2.08%
大文字化:
|
ボリューム (24 時間):